Case number 2019-1067
Amgen Inc. v. Hospira, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | AMGEN INC. v. HOSPIRA, INC. [OPINION - PRECEDENTIAL] [precedential] (0) |
| Mar 23, 2020 | 56 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [681009] [19-1067, 19-1102] [JAB] [Entered: 03/23/2020 02:35 PM] (1) |
| Mar 16, 2020 | 55 | ORDER filed denying [50] petition for en banc rehearing filed by Hospira, Inc. By: En Banc (Per Curiam). Service as of this date by the Clerk of Court. [679158] [JAB] [Entered: 03/16/2020 02:57 PM] (2) |
| Feb 28, 2020 | 54 | 18 paper copies of the response [53] received from Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. [675185] [JAB] [Entered: 02/28/2020 01:57 PM] (0) |
| Feb 27, 2020 | 53 | RESPONSE of Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited to the petition [50] filed by Appellant Hospira, Inc.. Service: 02/27/2020 by email. [675014] [19-1067] [John Labbe] [Entered: 02/27/2020 10:42 PM] (25) |
| Feb 13, 2020 | 52 | The court invites a response from Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited to the petition for en banc rehearing filed by Appellant in 19-1067. The response is due on or before 02/27/2020. [671011] [JAB] [Entered: 02/13/2020 11:00 AM] (1) |
| Jan 16, 2020 | 51 | 18 paper copies of the petition for en banc rehearing [50] received from Appellant Hospira, Inc. [663813] [JAB] [Entered: 01/16/2020 01:20 PM] (0) |
| Jan 15, 2020 | 50 | Petition for en banc rehearing filed by Appellant Hospira, Inc.. Service: 01/15/2020 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 01/17/2020 [663373] [19-1067] [Thomas Meloro] [Entered: 01/15/2020 01:59 PM] (52) |
| Dec 16, 2019 | 49 | JUDGMENT. AFFIRMED. Terminated on the merits after oral argument. COSTS: Each side bears its own costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [656661] [19-1067, 19-1102] [MJL] [Entered: 12/16/2019 09:18 AM] (2) |
| Dec 16, 2019 | 48 | OPINION filed for the court by Moore, Circuit Judge; Bryson, Circuit Judge and Chen, Circuit Judge. Precedential Opinion. [656659] [19-1067, 19-1102] [MJL] [Entered: 12/16/2019 09:17 AM] (24) |
| Sep 30, 2019 | 47 | Submitted after ORAL ARGUMENT by Mr. Thomas J. Meloro for Hospira, Inc. and John Labbe for Amgen Inc. and Amgen Manufacturing, Limited. Panel: Judge: Moore , Judge: Bryson , Judge: Chen. [639020] [JCP] [Entered: 09/30/2019 10:37 AM] (0) |
| Sep 16, 2019 | 46 | Response to notice of oral argument from the Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. [635862] [19-1067] [John Labbe] [Entered: 09/16/2019 04:27 PM] (3) |
| Sep 16, 2019 | 45 | Response to notice of oral argument from the Appellant Hospira, Inc.. [635842] [19-1067] [Thomas Meloro] [Entered: 09/16/2019 03:25 PM] (3) |
| Aug 21, 2019 | 44 | NOTICE OF ORAL ARGUMENT. Panel: 1910G. Case scheduled September 30, 2019 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 203. Response to Notice of Oral Argument due: 09/16/2019. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [629882] [JAB] [Entered: 08/21/2019 01:16 PM] (2) |
| May 16, 2019 | 43 | Notice from Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited regarding conflicts with oral argument. None. Service: 05/16/2019 by email. [607962] [19-1067] [John Labbe] [Entered: 05/16/2019 03:05 PM] (2) |
| May 15, 2019 | 42 | The following conflict dates submitted by Attorney Thomas J. Meloro for Appellant Hospira, Inc. have been accepted by the court: 07/08/2019, 07/09/2019, 07/10/2019, 11/04/2019, 11/07/2019. [607556] [JAB] [Entered: 05/15/2019 01:35 PM] (0) |
| May 14, 2019 | 41 | Notice from Appellant Hospira, Inc. regarding conflicts with oral argument. Service: 05/14/2019 by email. [607228] [19-1067] [Thomas Meloro] [Entered: 05/14/2019 02:59 PM] (4) |
| May 10, 2019 | 40 | 6 paper copies of the Reply Brief [28] received from Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. [606605] [CJF] [Entered: 05/10/2019 03:23 PM] (0) |
| May 10, 2019 | 39 | 6 paper copies of the Corrected Joint Appendix Brief (Vol. I - III) [33] received from Appellant Hospira, Inc. and Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. [606480] [CJF] [Entered: 05/10/2019 10:21 AM] (0) |
| May 10, 2019 | 38 | 6 paper copies of the Response and Reply Brief [27] received from Appellant Hospira, Inc.. [606479] [CJF] [Entered: 05/10/2019 10:19 AM] (0) |
| May 10, 2019 | 37 | 6 paper copies of the Opening Response Brief [26] received from Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. [606478] [CJF] [Entered: 05/10/2019 10:18 AM] (0) |
| May 10, 2019 | 36 | 6 paper copies of the Corrected Opening Brief [19] received from Appellant Hospira, Inc.. [606476] [CJF] [Entered: 05/10/2019 10:15 AM] (0) |
| May 9, 2019 | 35 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The notice of conflict with oral argument is due on or before 05/16/2019. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [606141] [JAL] [Entered: 05/09/2019 10:23 AM] (1) |
| May 9, 2019 | 34 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(1). [606140] [JAL] [Entered: 05/09/2019 10:23 AM] (0) |
| May 8, 2019 | 33 | MODIFIED ENTRY: CORRECTED JOINT APPENDIX FILED for Appellant Hospira, Inc. and Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. Number of Pages: 1432. Service: 05/08/2019 by email. [605915] --[Edited 05/09/2019 by JAL - Compliance review complete] [Thomas Meloro] [Entered: 05/08/2019 02:53 PM] (1432) |
| May 1, 2019 | 32 | NOTICE OF NON-COMPLIANCE: The submission of Appellant Hospira, Inc. and Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited, Joint Appendix [29], is not in compliance with the rules of this court (see attached). Compliant document is due on 05/08/2019. Service as of this date by the Clerk of Court.[604320] [JAL] [Entered: 05/01/2019 11:22 AM] (1) |
| Apr 29, 2019 | 29 | FILED from Cross-Appellants Amgen Inc., Amgen Manufacturing, Limited and Appellant Hospira, Inc.. Title: JOINT APPENDIX. Service: 04/29/2019 by email. [603801] [19-1067] This document is non-compliant. See Doc No.[32] [Thomas Meloro] [Entered: 04/29/2019 05:24 PM] (1457) |
| Apr 29, 2019 | 30 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Cross-Appellants Amgen Inc., Amgen Manufacturing, Limited and Appellant Hospira, Inc.. Service: 04/29/2019 by email. [603802] [19-1067] [Thomas Meloro] [Entered: 04/29/2019 05:28 PM] (3) |
| Apr 29, 2019 | 31 | Joint Statement of Compliance with Fed. Cir. R. 33 for Cross-Appellants Amgen Inc., Amgen Manufacturing, Limited and Appellant Hospira, Inc.. Service: 04/29/2019 by email. [603803] [19-1067] [Thomas Meloro] [Entered: 04/29/2019 05:29 PM] (3) |
| Apr 22, 2019 | 28 | MODIFIED ENTRY: REPLY BRIEF FILED for Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. Number of Pages: 8. Service: 04/22/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [602161] --[Edited 04/23/2019 by JAL - Compliance review complete] [John Labbe] [Entered: 04/22/2019 09:59 PM] (14) |
| Apr 1, 2019 | 27 | MODIFIED ENTRY: RESPONSE AND REPLY BRIEF FILED for Appellant Hospira, Inc. Number of Pages: 49. Service: 04/01/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [596977] --[Edited 04/02/2019 by JAL - Compliance review complete] [Thomas Meloro] [Entered: 04/01/2019 05:05 PM] (60) |
| Feb 19, 2019 | 26 | MODIFIED ENTRY: RESPONSE BRIEF FILED for Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. Number of Pages: 77. Service: 02/19/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [587280] --[Edited 02/25/2019 by JAL - Compliance review complete] [John Labbe] [Entered: 02/19/2019 11:47 PM] (155) |
| Feb 6, 2019 | 25 | **TEXT ONLY** ORDER granting motion to extend time to file brief [24] filed by Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. Cross-Appellants' principal and response brief due 02/19/2019. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [583884] [JAL] [Entered: 02/06/2019 04:12 PM] (0) |
| Jan 29, 2019 | 24 | MOTION of Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited to extend the time to 02/19/2019 to file the Amgen's Principal and Response Brief. [Consent: not addressed]. Service: 01/29/2019 by email. [581945] [19-1067] [John Labbe] [Entered: 01/29/2019 11:58 PM] (9) |
| Jan 11, 2019 | 23 | **TEXT ONLY** ORDER granting motion to extend time to file brief [21] filed by Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited's brief is due 02/05/2019. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [577550] [MMA] [Entered: 01/11/2019 09:58 AM] (0) |
| Jan 11, 2019 | 22 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: motion to extend time to file brief Docket No. [21], ERROR: Cross-Appellant's motion does not include a certificate of compliance. CORRECTION: Pursuant to FRAP 32(g)(1), motions must contain a certificate of compliance with the word count. Please ensure future motions include the certificate of compliance. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [577547] [MMA] [Entered: 01/11/2019 09:54 AM] (0) |
| Jan 10, 2019 | 21 | MOTION of Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited to extend the time to 02/05/2019 to file the Cross-Appellant's Principal and Response Brief. [Consent: unopposed]. Service: 01/10/2019 by email. [577273] [19-1067] [John Labbe] [Entered: 01/10/2019 11:36 AM] (6) |
| Dec 18, 2018 | 20 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: The addendum to Hospira's brief [19] was not text-searchable. CORRECTION: Pursuant to the court's Electronic Filing Procedures (established under FCR 25(c)(4)), documents must be text-searchable. Please ensure future filings are entirely text-searchable. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [572637] [MJL] [Entered: 12/18/2018 12:03 PM] (0) |
| Dec 13, 2018 | 19 | MODIFIED ENTRY: CORRECTED BRIEF FILED for Hospira, Inc. Number of Pages: 66. Service: 12/13/2018 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of the original brief. See Fed. Cir. R. 31. [571696]--[Edited 12/18/2018 by MJL - compliance review complete] [Thomas Meloro] [Entered: 12/13/2018 05:37 PM] (242) |
| Dec 13, 2018 | 18 | Notice of Correction to the Brief Doc No. [17] for Appellant Hospira, Inc.. Service: 12/13/2018 by email. [571689] [19-1067] [Thomas Meloro] [Entered: 12/13/2018 05:30 PM] (3) |
| Dec 10, 2018 | 17 | FILED from Appellant Hospira, Inc.. Title: OPENING BRIEF. Service: 12/10/2018 by email. [570640] [19-1067]. This brief has been corrected. See Doc. No. [19]. [Thomas Meloro] [Entered: 12/10/2018 06:05 PM] (217) |
| Oct 25, 2018 | 16 | Entry of appearance for Heather M. Schneider as of counsel for Appellant Hospira, Inc.. Service: 10/25/2018 by email. [560486] [19-1067] [Heather Schneider] [Entered: 10/25/2018 05:42 PM] (2) |
| Oct 25, 2018 | 15 | Entry of appearance for Michael W. Johnson as of counsel for Appellant Hospira, Inc.. Service: 10/25/2018 by email. [560484] [19-1067] [Michael Johnson] [Entered: 10/25/2018 05:37 PM] (2) |
| Oct 25, 2018 | 14 | Certificate of Interest for the Appellant Hospira, Inc.. Service: 10/25/2018 by email. [560480] [19-1067] [Thomas Meloro] [Entered: 10/25/2018 05:32 PM] (3) |
| Oct 25, 2018 | 13 | Docketing Statement for the Appellant Hospira, Inc.. Service: 10/25/2018 by email. [560478] [19-1067] [Thomas Meloro] [Entered: 10/25/2018 05:28 PM] (4) |
| Oct 25, 2018 | 12 | Entry of appearance for Thomas J. Meloro as principal counsel for Appellant Hospira, Inc.. Service: 10/25/2018 by email. [560476] [19-1067] [Thomas Meloro] [Entered: 10/25/2018 05:24 PM] (2) |
| Oct 25, 2018 | 11 | Docketing Statement for the Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. Service: 10/25/2018 by email. [560475] [19-1067] [John Labbe] [Entered: 10/25/2018 05:11 PM] (5) |
| Oct 25, 2018 | 10 | Entry of appearance for Mark H. Izraelewicz as of counsel for Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. Service: 10/25/2018 by email. [560471] [19-1067] [Mark Izraelewicz] [Entered: 10/25/2018 05:01 PM] (2) |
| Oct 25, 2018 | 9 | Entry of appearance for Julianne M. Hartzell as of counsel for Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. Service: 10/25/2018 by email. [560466] [19-1067] [Julianne Hartzell] [Entered: 10/25/2018 04:36 PM] (2) |
| Oct 25, 2018 | 8 | Entry of appearance for Kevin M. Flowers as of counsel for Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. Service: 10/25/2018 by email. [560464] [19-1067] [Kevin Flowers] [Entered: 10/25/2018 04:33 PM] (2) |
| Oct 25, 2018 | 7 | Certificate of Interest for the Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. Service: 10/25/2018 by email. [560461] [19-1067] [John Labbe] [Entered: 10/25/2018 04:30 PM] (3) |
| Oct 25, 2018 | 6 | Entry of appearance for Thomas F. Lavery IV as of counsel for Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. Service: 10/25/2018 by email. [560460] [19-1067] [John Labbe] [Entered: 10/25/2018 04:28 PM] (2) |
| Oct 25, 2018 | 5 | Entry of appearance for Wendy A. Whiteford as of counsel for Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. Service: 10/25/2018 by email. [560457] [19-1067] [John Labbe] [Entered: 10/25/2018 04:24 PM] (2) |
| Oct 25, 2018 | 4 | Entry of appearance for John R. Labbe as principal counsel for Cross-Appellants Amgen Inc. and Amgen Manufacturing, Limited. Service: 10/25/2018 by email. [560455] [19-1067] [John Labbe] [Entered: 10/25/2018 04:18 PM] (2) |
| Oct 23, 2018 | 3 | Official caption revised to reflect cross-appeal. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by the Clerk of Court. [559503] [MJL] [Entered: 10/23/2018 12:11 PM] (0) |
| Oct 23, 2018 | 2 | Note to file: The following cases are consolidated: 19-1067 (Lead) with 19-1102 (Cross-Appeal). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [559502] [19-1067, 19-1102] [MJL] [Entered: 10/23/2018 12:10 PM] (0) |
| Oct 11, 2018 | 1 | Appeal docketed. Received: 10/03/2018. [556411]Entry of Appearance due 10/25/2018. Certificate of Interest due 10/25/2018. Docketing Statement due 10/25/2018. Appellant's brief due 12/10/2018. [MJL] [Entered: 10/11/2018 03:13 PM] (41) |
